Sugi Predict

Sugi Predict / Compounds / SCHEMBL3337129

SCHEMBL3337129

SCHEMBL3337129

NC(=O)c1ncn2c(=O)n(CCCCl)nnc12

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ PABPC1 P11940 1/20 0.63
▸ CA12 O43570 3/20 0.38
▸ CA1 P00915 3/20 0.38
▸ CA2 P00918 3/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ SLC9A1 P19634 1/20 0.35
▸ ADORA2B P29275 1/20 0.32
▸ CSNK2A2 P19784 1/20 0.32
▸ CSNK2B P67870 1/20 0.32
▸ CSNK2A1 P68400 1/20 0.32
▸ CSNK2A3 Q8NEV1 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ PNP P00491 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mitozolomide SCHEMBL97695 0.93 MEN1 (0.64) MEN1KMT2APABPC1CA12CA1
SCHEMBL13027731 0.90 MEN1 (0.71) MEN1KMT2APABPC1CA12CA1
SCHEMBL13027994 0.88 MEN1 (0.63) MEN1KMT2APABPC1CA12CA1
SCHEMBL2891553 0.86 MEN1 (0.66) MEN1KMT2APABPC1CA12CA1
SCHEMBL13027978 0.86 MEN1 (0.62) MEN1KMT2APABPC1CA12CA1
SCHEMBL13028036 0.85 MEN1 (0.64) MEN1KMT2APABPC1CA12CA1
SCHEMBL2892060 0.85 MEN1 (0.64) MEN1KMT2APABPC1CA12CA1
SCHEMBL3334065 0.85 MEN1 (0.64) MEN1KMT2APABPC1CA12CA1
SCHEMBL13028034 0.85 MEN1 (0.64) MEN1KMT2APABPC1CA12CA1
SCHEMBL3336560 0.85 MEN1 (0.68) MEN1KMT2APABPC1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143340-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER SCHERING CORPORATION 2010-06-10 — — US claimed
EP-2121018-A2 TREATING CANCER WITH ANTI-IGF1R ANTIBODY 19D12=SCH 717454 SCHERING CORPORATION (US) 2009-11-25 — — EP claimed
WO-2008076257-A2 TREATING CANCER WITH ANTI-IGFLR ANTIBODY 19D12 = SCH 717454 SCHERING CORPORATION (US) 2008-06-26 — — WO claimed
US-5260291-A Tetrazine derivatives CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1993-11-09 — — US claimed
EP-3116507-B1 COMPOUNDS FOR ORAL TREATMENT OF BRAIN TUMORS KADMON CORP LLC (US) 2021-05-26 — — EP disclosed
US-10080752-B2 Treatment of brain and central nervous system tumors KADMON CORPORATION, LLC (US) 2018-09-25 — — US disclosed
US-20170071943-A1 TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS KADMON CORPORATION, LLC 2017-03-16 — — US disclosed
US-8450479-B2 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use PHARMINOX LIMITED (GB) 2013-05-28 — — US disclosed
US-8450479-B2 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use PHARMINOX LIMITED (GB) 2013-05-28 — — US disclosed
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use PHARMINOX LIMITED (GB) 2010-11-11 — — US disclosed
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use PHARMINOX LIMITED (GB) 2010-11-11 — — US disclosed
US-20100143340-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER SCHERING CORPORATION 2010-06-10 — — US disclosed
WO-2009077741-A2 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE PHARMINOX LIMITED (GB) 2009-06-25 — — WO disclosed
WO-2008076257-A2 TREATING CANCER WITH ANTI-IGFLR ANTIBODY 19D12 = SCH 717454 SCHERING CORPORATION (US) 2008-06-26 — — WO disclosed
EP-1896505-A2 ANTI-IGF1R ANTIBODY FORMULATIONS SCHERING CORPORATION (US) 2008-03-12 — — EP disclosed
WO-2006138315-A2 ANTI-IGF1R ANTIBODY FORMULATIONS SCHERING CORPORATION (US) 2006-12-28 — — WO disclosed
US-20060286103-A1 Stable antibody formulation MERCK SHARP & DOHME CORP. 2006-12-21 — — US disclosed
US-20060205810-A1 Platinum therapeutic combinations SCHERING CORPORATION 2006-09-14 — — US disclosed
WO-2006057998-A1 BINARY ANTITUMOR COMPOSITIONS PLATINUM (IV) DERIVATIVES SCHERING CORPORATION (US) 2006-06-01 — — WO disclosed
US-5260291-A Tetrazine derivatives CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1993-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170071943-A1 TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS ERBB2, EGFR, ERBB3 MEN1 2161/4885KMT2A 315/4885PABPC1 4868/4885
US-10080752-B2 Treatment of brain and central nervous system tumors ERBB2, EGFR, ERBB3 MEN1 2161/4885KMT2A 315/4885PABPC1 4868/4885
US-20100143340-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER TP53, KLK3, CD44 MEN1 766/4885KMT2A 2490/4885PABPC1 916/4885
US-20100286088-A1 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use MKI67, CCNI, CDK4 MEN1 3049/4885KMT2A 209/4885PABPC1 3755/4885
US-20060205810-A1 Platinum therapeutic combinations MGMT, PARP2, TYMP MEN1 402/4885KMT2A 1057/4885PABPC1 736/4885
US-20060286103-A1 Stable antibody formulation FCGR3B, FCGR2A, FCGR1A MEN1 1331/4885KMT2A 2046/4885PABPC1 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.